ProCE Banner Activity

Experts Answer Key Questions on Novel Therapies for Hemophilia Prophylaxis

Clinical Thought

What questions do you have on hemophilia prophylaxis? Read expert responses to questions from a live event at the Thrombosis & Hemostasis Summit of North America on new therapies for hemophilia prophylaxis.

Released: June 05, 2024

Expiration: June 04, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Sanofi.

Sanofi

Disclosure

Primary Author

Mark T Reding, MD

Professor of Medicine
Division of Hematology, Oncology, and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center
Minneapolis, Minnesota

Mark T. Reding, MD: consultant/advisor/speaker: Bayer, Biomarin, CSL Behring, Genentech, HEMA Biologics, Novo Nordisk, Sanofi, Spark, Takeda; researcher: Bayer, Biomarin.

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children’s Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Guy Young, MD: consultant/advisor/speaker: Biomarin, CSL Behring, Genentech/Roche, Hema Biologics, Novo Nordisk, Octapharma, Pfizer, Sanofi, Spark, Takeda.